Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Net Income (2018 - 2025)

X4 Pharmaceuticals' Net Income history spans 8 years, with the latest figure at -$23.9 million for Q4 2025.

  • For Q4 2025, Net Income rose 39.92% year-over-year to -$23.9 million; the TTM value through Dec 2025 reached -$79.2 million, down 111.48%, while the annual FY2025 figure was -$79.2 million, 111.48% down from the prior year.
  • Net Income reached -$23.9 million in Q4 2025 per XFOR's latest filing, up from -$29.8 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $90.8 million in Q2 2024 to a low of -$55.7 million in Q2 2023.
  • Average Net Income over 5 years is -$20.0 million, with a median of -$22.9 million recorded in 2022.
  • The largest YoY upside for Net Income was 263.04% in 2024 against a maximum downside of 1492.02% in 2024.
  • A 5-year view of Net Income shows it stood at -$30.2 million in 2021, then increased by 3.65% to -$29.1 million in 2022, then skyrocketed by 34.27% to -$19.1 million in 2023, then crashed by 108.16% to -$39.8 million in 2024, then skyrocketed by 39.92% to -$23.9 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Net Income are -$23.9 million (Q4 2025), -$29.8 million (Q3 2025), and -$25.7 million (Q2 2025).